Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Ophthalmic Res ; 2022 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-36315988

RESUMO

INTRODUCTION: To investigate the changes in the retina and choroid of children after 650 nm low-level red light therapy (LLRLT). METHODS: In this prospective study, 25 subjects in the Shanghai Eye and ENT Hospital of Fudan University were included from August 2021 to September 2021. One eye was randomly selected to receive LLRLT for 3 minutes. Swept-source optical coherence tomography (OCT) and OCT angiography (OCTA) were used to measure retinal fovea perfusion density (RFPD), retinal fovea thickness (RFT), choroidal fovea blood flow (CFBF), and choroidal fovea thickness (CFT) before LLRLT, 5 minutes and 1 hour after LLRLT. Baseline characteristics between LLRLT and non-LLRLT eyes were compared. Changes in the retinal and choroidal parameters were analyzed by ANCOVA models. SAS software was used for data analysis. The difference was considered statistically significant if p < 0.05. RESULTS: There was no difference in baseline characteristics between LLRLT eyes and non-LLRLT eyes. The RFPD in LLRLT eyes significantly increased 5 minutes after LLRLT and the increment was 1.70±0.83 % (p = 0.0389). The RFPD significantly decreased from 5 minutes to 1 hour after LLRLT with a mean of -2.62±0.86 % decrement (p = 0.0031). The RFPD levels returned to baseline at 1 hour after LLRLT (p = 0.8646). However, compared with insignificant RFPD changes in non-LLRLT eyes, there was no significant difference in RFPD changes at any sampling point. No significant changes in RFT, CFBF, and CFT were found in LLRLT eyes at each sampling point. CONCLUSION: Although LLRLT has no effect on the choroid, it may cause a short-term transient increase in RFPD. It will provide theoretical support for the role of LLRLT in myopia control.

2.
ACS Appl Mater Interfaces ; 11(51): 48290-48299, 2019 Dec 26.
Artigo em Inglês | MEDLINE | ID: mdl-31802657

RESUMO

A novel drug-delivery nanosystem based on near-infrared (NIR) light-degradable antimony nanoparticles (AMNP) have been developed for synergistic chemo-phototherapy in vitro. The monodispersed AMNP were synthesized by using a simple and cost-effective method. Positively charged doxorubicin hydrochloride (DOX) was loaded onto the negatively charged surface of AMNP via electrostatic interaction and finally modified by polyacrylic acid (PAA) to enhance biocompatibility. Under NIR (808 nm) laser irradiation of the AMNP-DOX-PAA nanosystem, not only was high photothermal conversion efficiency of AMNP achieved but also pH-dependent DOX release was enhanced due to laser-induced hyperthermia. As a consequence, almost all of the HeLa cells (around 97%) were killed because of the combined effects of chemotherapy and photothermal therapy. More interestingly, AMNP showed very fast (about 10 min) laser-induced degradation that may help to minimize long-term toxicity after therapy by using same-wavelength NIR laser irradiation (808 nm). Computational total energy calculations and molecular dynamics simulations based on density functional theory (DFT) suggest that the NIR laser irradiation induces a photothermally activated reaction on the surface of AMNP in water, which can lead to surface degradation via the formation of Sb-H bonds first and then Sb-OH bonds upon further increase of temperature. This work demonstrates a simple platform that has potential applications for synergistic and highly effective chemo-photothermal therapy based on photodegradable nanoparticles.


Assuntos
Antimônio/química , Doxorrubicina/química , Sistemas de Liberação de Medicamentos/métodos , Nanopartículas/química , Células HeLa , Humanos , Microscopia Eletrônica de Transmissão , Fototerapia/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA